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Glycodendrimers as Potential 
Multitalented Therapeutics in 
Alzheimer’s Disease
Oxana Klementieva
Abstract
Finding successful therapies for the treatment of Alzheimer’s disease (AD) is 
one of the most challenging tasks existing for human health. Several drugs have 
been found and validated in preclinical studies with some success, but not with the 
desired breakthroughs in the following clinical development phases. AD causes 
multiple brain dysfunctions that can be described as a brain organ failure, result-
ing in significant cognitive decline. Aggregation of amyloid proteins and neuronal 
loss are the hallmarks of AD. Thus, one of the strategies to treat AD is to find a 
multifunctional drug that may combine both anti-aggregation and neuroprotective 
properties. Such a candidate could be chemically modified dendrimers. Dendrimers 
are branched, nonlinear molecules with multiple reactive groups located on their 
surface. Chemical modification of reactive surface groups defines the property of 
the dendrimers. In this chapter, I will discuss poly(propylene imine) dendrimers 
with the surface functionalized with histidine and maltose as an example of a 
multifunctional therapeutic drug candidate able to protect the memory of AD 
transgenic model mice.
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1. Introduction
Alzheimer’s disease (AD) is a complex neurological disease, which already in its 
earliest clinical phase is characterized by remarkable memory impairment. Multiple 
pieces of evidence suggest that in AD, memory impairment begins with dysfunction 
of synapses, a unique characteristic of nerve cells. Early neurochemical analyses of 
AD brain tissue revealed that the deficits in numerous neurotransmitters (including 
corticotropin-releasing factor, somatostatin, GABA, and serotonin) and the early 
symptoms correlate with dysfunction of cholinergic and glutamatergic synapses [1]. 
In addition to the deficits of the transmitters, many other biochemical and morpho-
logical indicators suggest that in early AD, synapses are under attack as reviewed 
in [2]. It has been shown that in biopsied AD cortex, there is a significant decrease 
in the numerical density of synapses in the brain and the number of synapses per 
cortical neuron [3]. The amyloid cascade hypothesis, one of the widely accepted 
theories, suggests that progressive accumulation and aggregation of amyloid-β 
proteins (Aβ) could be the main cause of AD, which triggers AD neuropathology. 
Aβ proteins are the proteolytic products of amyloid precursor protein (APP), a 
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type-I transmembrane protein which is highly expressed in neurons, known to 
regulate synaptic function and neurite outgrowth [4]. There are two main alterna-
tive enzymatic pathways to process APP [5]:
1. Non-amyloidogenic pathway, where APP is subjected to consecutive cleavage 
by α-and γ-secretases that cut APP within the Aβ fragment
2. Amyloidogenic APP pathway, where APP is subjected to cleavage by β-and 
γ-secretases generating Aβ, a mix of short peptides ranging from 38 to 43 
amino acids in length able to form polymorphous aggregates, so-called oligom-
ers, and fibrils [6]
APP processing is regulated by neuronal activity, and neuronal activity may 
favor β-secretase-mediated amyloidogenic cleavage of APP during which Aβ 
proteins are generated [7]. It was accepted that after APP cleavage, Aβ peptides are 
first secreted, and then, extracellularly, soluble Aβ peptides aggregate into amyloid 
plaques. This extracellular Aβ, which is the main constituent of amyloid plaques, 
is thought to be toxic to the neurons. More recently, the intraneuronal Aβ has been 
demonstrated and reported to be involved in neuronal damage [8, 9]. It has been 
demonstrated that Aβ attacks synapses, small membranous protrusions that permit 
one neuron to pass a signal (electrical or chemical) to another neuron.
It has been shown that synaptic activity may affect Aβ secretion [5], and it 
has been hypothesized that synaptic activity may stimulate the generation of Aβ 
although why this occurs and whether Aβ might have a normal function in neuronal 
synapse have not been understood well [10]. Strikingly, it has been shown that Aβ 
selectively binds to synapses when added to cultured neurons [11]. Further, the level 
of Aβ is shown to be increased in synaptosomes in early AD [12]. Immunoelectron 
microscopy and high-resolution immunofluorescence microscopy studies show that 
this early subcellular Aβ accumulation leads to progressive damage of neurites and 
synapses [13]. Thus, synapses could be sites of early accumulation of pathogenic Aβ. 
It is believed that soluble Aβ oligomers rather than monomeric or fibrillar Aβ are the 
main neurotoxic species. However, a structure of neurotoxic Aβ oligomers and the 
nature of their effects on synapses are not identified [14].
Despite advances, the efforts to target neurotoxic Aβ oligomers in the brain are 
confounded by high polymorphism of amyloid structures [15]. Oligomer specific 
antibodies may interact mainly with a specific type of Aβ conformers against 
which these antibodies were produced [16]. Therefore, to target polymorphic Aβ 
oligomers, a cocktail from several antibodies might be required. Another way to 
modulate Aβ aggregation could be via establishing H-bond interactions [17] to favor 
the formation of less toxic Aβ species [18].
To fight a brain disease such as AD pathology, both synapse protection and 
anti-amyloid modulation would be desired properties of a possible therapeutic drug. 
However, to protect synapses and to modulate Aβ aggregation, amyloid aggregation 
modulator and neuroprotective therapeutics have to be delivered to the synapse. One 
way to deliver both therapeutic molecules is to use a compound which may carry both 
molecules simultaneously. Such multifunctional compound could be a dendrimer.
Dendrimers are three-dimensionally branched, globular macromolecules built 
by a series of iterative steps from a small core molecule which defines the type of the 
dendrimer [19]. They were first synthesized and described in 1978 [20], and since 
then dendrimers are in focus, due to their outstanding complexation properties. 
The most important features of dendrimers are controlled molecular structure, 
nanoscopic size, and high tunable availability of multiple functional groups at the 
dendrimer surface. Dendrimers are composed of three elements: a core branched 
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dendron and terminal groups which could be used for dendrimer functionalization. 
The number of surface functional groups of the dendrimer depends on the degree 
of dendrimer branching (Figure 1). For example, PPI or PAMAM dendrimers of the 
Figure 1. 
Structure and chemical modification of dendrimers. (A) Molecular structure of poly(propylene imine) 
dendrimers of the fourth generation. Circle 1 shows the core; circle 2 indicates branching points of the 
dendrimers; circle 3 shows the terminal groups, R1 and R2. Fifth-generation PPI dendrimer (Eindhoven, the 
Netherlands) was renamed as fourth-generation (G4) PPI dendrimers following the uniform nomenclature 
[59]. (B) Example of surface modification of the PPI dendrimer. A reaction pathway shows the synthesis of 
G4 histidine-maltose PPI dendrimers first with histidine (R1) and then with maltose (R2). Conjugation with 
histidine and maltose neutralizes the positive charge of the primary amino groups [27].
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second generation have 16 functional groups on their surface, the third generation 
has 32, and the fourth dendrimer generation has 64 functional groups. Strikingly, 
the number of terminal groups increases exponentially, while the size increases 
linearly. The terminal groups on the dendrimer surface can be used for surface 
modification and dendrimer functionalization. Such modifications could change 
dendrimers’ surface charge and, for example, reduce toxicity associated with a 
cationic surface charge as reviewed by Appelhans et al. [21]. Dendrimers are most 
commonly synthesized using divergent or convergent different synthetic pathways 
[22]. Importantly, the high tunability of dendrimers’ surface allows endless pos-
sibilities for dendrimers’ biomedical applications, for example, for pharmaceuti-
cal applications, the terminal groups can be functionalized with different active 
conjugates such as specifically targeting antibodies, drugs, metal ions or imaging 
agents, and more [23]. Moreover, several research groups demonstrated that some 
types of dendrimers are able to cross the BBB [24–27], showing their applicability 
for the research and possibly treatment of brain diseases.
In the present chapter, I summarize the experimental evidence showing that 
functionalized poly(propylene imine) dendrimers may provide multitargeting 
properties for dendrimers increasing their potential for the treatment of AD.
2. Amyloid aggregation and dendrimers
According to the amyloid cascade hypothesis, Aβ peptides are important players 
triggering the AD development. Multiple in vitro studies have demonstrated that 
the Aβ peptides can form fibrils and other aggregates called oligomers. The forma-
tion of insoluble Aβ fibril follows a nucleation-dependent polymerization mecha-
nism (Figure 2) as described [28]. The formation of soluble Aβ oligomers in vivo is 
largely unknown; it is believed that soluble Aβ oligomers may precede fibril forma-
tion [29] and are more toxic than mature Aβ fibrils [30].
In the search for drugs that would inhibit neuronal death in Alzheimer’s disease, 
one of the ways one can use is to find compounds that interfere with Aβ, cleaning 
the brain tissues from neurotoxic Aβ oligomers. It has been demonstrated that PPI 
dendrimers modified with maltose are capable of interfering with the amyloid 
formation in vitro [18, 26, 31, 32]. Amyloid fibril formation is usually monitored 
Figure 2. 
Example of amyloid fibrils and amyloid oligomers. (A) Electron micrographs of the Aβ(1–40) fibrils  
(B) Aβ(1–40) oligomers prepared as described [9]. Scale bar is 200 nm.
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using the fluorescence dye thioflavin T (ThT). The dye becomes fluorescent when 
interacting with the ordered β-sheet structures characteristic for amyloid fibrils. 
With the fibril growth, the ThT fluorescence increases until its value reaches a 
plateau. Figure 3 demonstrates the sigmoid-shaped line corresponding to the ThT 
kinetics corresponding to the fibril growth of Aβ(1–40), where the lag (nucleation) 
phase is followed by the elongation phase and plateau; when all ThT molecules have 
intercalated into β-sheets of the amyloid fibrils, the aggregation kinetics of amy-
loids is reviewed [33].
PPI dendrimers modified with maltose may, in the case of Aβ(1–40) or Aβ(1–
42), interfere with amyloid fibril formation in a concentration-dependent manner, 
indicating that maltose PPI dendrimers bind amyloid proteins [18]. Figure 4 dem-
onstrates the ThT fluorescent kinetics of Aβ(1–40) and Aβ(1–42) in the presence 
of maltose PPI dendrimers. As expected, Aβ alone forms the typical amyloid fibrils 
[29]. However, when the maltose PPI dendrimers are present, the morphology of 
amyloid fibrils is altered, demonstrating binding of the dendrimers to Aβ [18, 26, 
34, 35]. The electron micrograph shows the morphology of amyloid fibril in the 
presence of maltose PPI dendrimers. Fibril clumps were generated by incubating 
maltose PPI dendrimers with Aβ(1–40). As it has been suggested that dendrimers 
interact with Aβ thus, fibrils seem to be varnished by maltose dendrimers and 
clumped together, and importantly, no Aβ oligomers were observed in the presence 
of maltose PPI dendrimers [18]. Thus it is reasonable to think that maltose den-
drimers interacting with Aβ may form hybrid fibrils, shifting the balance between 
oligomeric and fibrillar forms of Aβ toward less toxic hybrid products.
Dendrimers’ intrinsic toxicity is an important issue in relation to their potential 
biological applications [36]. It was observed that unmodified PPI dendrimers 
have high intrinsic toxicity for cells [37, 38]. It was hypothesized that this toxicity 
could be related to the dendrimer capacity of establishing strong interactions of 
electrostatic nature [39]. It has been demonstrated that dendrimers with a surface 
decorated by polysaccharides, such as maltose or maltotriose, confer less toxicity 
[40, 41]. The charge of the dendrimer covered by polysaccharides is close to neutral; 
Figure 3. 
Characteristic aggregation curve for amyloid fibril formation. Sigmoid-shaped curve 5 μM recombinant 
Aβ(1–42) kinetics as detected by ThT fluorescence over time and displayed as % of total ThT binding. Area (A) 
corresponds to the lag phase (nucleation), area (B) corresponds to the growing phase, and area (C) corresponds 
to final ThT fluorescence plateau. Inset: molecular structure of ThT.
Neuroprotection - New Approaches and Prospects
6
thus the interaction of dendrimer with other biomolecules is driven by hydrogen 
bonds, which is less strong; therefore, dendrimers covered by polysaccharides are 
less toxic [37, 38, 40].
In collaborations between the research groups of Dietmar Appelhans (Leibniz 
Institute of Polymer Research, Dresden, Germany), Josep Cladera (Autonomous 
University of Barcelona, Spain), and Isidro Ferrer in Barcelona (University of 
Barcelona, Spain), it has been shown that distinct PPI dendrimers with electroneu-
tral maltose shell, with cationic maltose or maltotriose shell, were tested against 
amyloid toxicity in vivo and in vitro. The evaluation of the toxicity of Aβ in the 
presence of PPI maltose dendrimers showed that the dendrimers could significantly 
reduce the Aβ toxicity compared to Aβ alone [26].
Interestingly, only the electroneutral maltose dendrimers were able to reduce the 
toxicity of Alzheimer’s disease brain extracts in cultured SH-SY5Y neuroblastoma 
cells [26]. Moreover, maltose PPI dendrimers with electroneutral or cationic surface 
penetrated the cytoplasm of cultured cells. Additionally, they penetrated inside the 
brain when administered to AD transgenic mice intranasally [26]. These PPI malt-
ose dendrimers were able to modify amyloid plaque load in the brains of AD trans-
genic animals, showing anti-amyloid potential for in vivo applications. However, 
the studied maltose PPI dendrimers could not reverse memory impairment in APP/
PS1 mice following chronic administration. Strikingly, cationic maltose dendrimers 
were neurotoxic in vivo and caused cognitive decline in non-transgenic mice [26]. 
Taken together, these results suggest that maltose PPI dendrimers require further 
optimization of biocompatibility.
3.  Modified PPI dendrimers as potential multifunctional therapeutics 
for Alzheimer’s disease
As it has been mentioned at the beginning of the chapter, Alzheimer’s disease is 
a fatal neurodegenerative disorder. AD is characterized by a decade-long presymp-
tomatic phase, and it is during the presymptomatic phase, before synaptic damage 
and neuronal loss, that therapies are most likely to be effective [42]. Thus, a preven-
tive treatment which could protect synapses and reduce the neurotoxicity of Aβ 
Figure 4. 
Effect of G4 histidine-maltose PPI dendrimers on the fibrillization of Aβ. (A) Aggregation of 20 μM Aβ(1–40) 
in the absence (red) and the presence of histidine-maltose PPI dendrimers. (Magenta) 20 μM Aβ(1–40) 
in the presence of dendrimers at dendrimer/peptide ratio = 0.1, (blue) 20 μM Aβ(1–40) in the presence of 
dendrimers at dendrimer/peptide ratio = 1. (B) Aggregation of 25 μm Aβ(1–42) in the absence (red) and in 
the presence of histidine-maltose PPI dendrimers. (Magenta) 25 μM Aβ(1–42) in the presence of dendrimers 
at dendrimer/peptide ratio = 0.1, (blue) 25 μM Aβ(1–42) in the presence of dendrimers at dendrimer/peptide 
ratio = 1. The temperature was 37°C, the pH was set to 7.4, and the concentration of ThT was 6 μM (adapted 
with permission from [27]).
7Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.88974
oligomers is one such strategy. Such successful drug candidates for AD treatment 
have to possess both anti-amyloidogenic and neuroprotective properties. Therefore, 
a modification of maltose dendrimers with a molecule with neuroprotective 
characteristics was the next logical step in search of the new drug candidate for the 
treatment of AD.
To further improve the pharmacological properties of maltose PPI dendrimers, 
it was decided to modify PPI dendrimers of the fourth generation with maltose and 
histidine. Maltose was used due to anti-amyloidogenic properties; histidine was 
added due to several reasons: it is selectively transported through the BBB [43]. 
Histidine has chelating properties for Cu2+ ions [44]. Thus these properties were 
considered to be important since Cu ion dyshomeostasis may play a detrimental role 
in AD progression [45], and importantly, histidine has been shown to have some 
neuroprotective capacity [46]. After the modification, G4 PPI dendrimers modified 
with maltose and histidine were supposed to possess both anti-amyloid and neuro-
protective properties simultaneously.
Figure 5. 
Effect of G4 histidine-maltose PPI dendrimers on Aβ morphology. (A) Electron microscopy micrographs of 
25 μM Aβ(1–40) incubated at pH 7.4 for 24 h. (B) 25 μM Aβ(1–40) incubated at pH 7.4 in the presence of G4 
histidine-maltose PPI dendrimers at the ratio 1 to 1. (C) Aβ(1–42) incubated at pH 7.4 for 24 h. (D) Aβ(1–42) 
incubated in the presence of G4 histidine-maltose PPI dendrimers (clumped fibrils). Scale bar is 200 nm.
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In vitro evaluations demonstrated that histidine-maltose PPI dendrimers could 
interact with Aβ. As maltose PPI dendrimers, G4 histidine-maltose PPI dendrimers 
did not prevent fibril formation but clump Aβ fibrils (Figure 5). Importantly, small 
oligomeric aggregates were not present in the studied suspensions in the presence 
of the dendrimers. Interestingly, the intensity of ThT was significantly decreased 
following the aggregation of Aβ probably due to the competition of the dendrimers 
with ThT for binding to Aβ(1–40) or due to change of structure, resulting in lower 
ThT fluorescence quantum yield [47, 48]. To test if G4 histidine-maltose PPI den-
drimers could reduce the neurotoxicity of Aβ, primary neurons derived from wild-
type mouse were treated with 1 μM Aβ(1–42) in the presence of the dendrimers 
at the ratio 1 to 1. As it was demonstrated by cell viability assay, histidine-maltose 
PPI dendrimers significantly reduced the neurotoxicity of soluble Aβ oligomers 
[27]. Figure 6 shows the neuronal viability in the presence of the dendrimers and 
Aβ(1–42) oligomers as assessed by a lactate dehydrogenase (LDH) activity assay. 
1 μM G4 histidine-maltose PPI dendrimers were added to primary neurons and 
incubated 24 h before the assay; as it was documented, the dendrimers alone were 
not toxic to the neurons. 1 μM recombinant Aβ(1–42) monomers, oligomers, and 
fibrils were added to primary neurons and incubated 1 h at 37°C in the presence and 
the absence of dendrimers. The results demonstrate that G4 histidine-maltose PPI 
dendrimers significantly reduced the toxicity of Aβ(1–42) for primary neurons.
In vivo evaluations demonstrated that chronic treatment with histidine-maltose 
PPI dendrimers of APP/PS1 mice prevented AD-related memory impairment [27]. 
Figure 7 shows the results of the memory test after the treatment. APP/PS1 mice 
harbor two human genes: APP with the KM670/671NL, the Swedish mutation, 
and PSEN1 with the L166P mutation [49]. In APP/PS1 mice, human Aβ increases 
with age, but Aβ42 is preferentially generated over Aβ40, and the expression of the 
human APP transgene is approximately 3-fold higher than the endogenous murine 
APP [50]. For the treatment, APP/PS1 and wild-type mice were randomly divided 
into four groups, two groups (transgenic and wild type) were treated intranasally 
with histidine-maltose PPI dendrimers, and two groups (transgenic and wild type) 
were given intranasally phosphate saline. Administration lasted 3 months until 
animals reached the age of 6 months, the age when the first cognitive decline is 
detected [51]. Memory evaluation tests were performed at the end of treatment 
using two object recognition tests in a VmazeR as described [51].
Figure 6. 
G4 histidine-maltose PPI dendrimers reduce the toxicity of Aβ oligomers for cultured primary neurons. (A) ThT 
fluorescence variation was used to monitor aggregation of 10 μM Aβ(1–42) in PBS at 37°C (black line); red 
line corresponds to ThT alone. The arrows indicate the time when aliquots of Aβ(1–42) were taken for neuronal 
viability assay. Aβ-M, a monomeric form of Aβ(1–42); Aβ-O, an oligomeric form of Aβ(1–42); Aβ-F, mature 
fibrils of Aβ(1–42); (B) 1 μM of G4 histidine-maltose PPI dendrimers were added to primary neurons and 
incubated 24 h before a cell viability assay. Cell viability was assessed by a lactate dehydrogenase activity assay. 
For the assay, 1 μM Aβ(1–42) of monomers, oligomers, and fibrils were added to wild-type primary neurons 
and incubated 1 h at 37°C. statistics: one-way ANOVA followed by Tukey’s post hoc test; data are expressed as 
mean ± SD. Primary neurons were derived from the brains of wild-type mouse embryos and cultured for 19 days. 
The experiment was performed in triplicate, one embryo per replica (adapted with permission from [27]).
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Figure 7. 
G4 histidine-maltose PPI dendrimers can protect memory in vivo. Memory performance in the V-maze shows 
significant improvement after preventive treatment with histidine-maltose PPI dendrimers. Treatment procedure: 
at the age of 3 months, animals were randomly divided into four groups; two groups control and APP/PS1 mice 
were given intranasally 5 μL of PBS, and two groups received intranasally 5 μg/day of G4 histidine-maltose PPI 
dendrimers (dendrimers). Treatment lasted 3 months until animals reached the age of 6 months when APP/PS1 
mice display cognitive impairment [51]. Statistics: two-way ANOVA with genotype and treatment as between 
factors followed by Tukey’s post hoc test; data are expressed as mean ± SEM (adapted with permission from [27]).
Figure 8. 
G4 histidine-maltose PPI dendrimers protect synapses in vivo. (A) Synapse is a junction between two neurons, 
which consist of pre- and postsynaptic terminals characterized by specific pre- and postsynaptic proteins. 
Synaptophysin was used to assess presynapse, while drebrin was used to evaluate postsynapse. Brain tissue 
homogenates of control mice and mice treated with G4 histidine-maltose PPI dendrimers (dendrimers) were 
analyzed using Western blotting; β-actin was used for protein normalization. Statistics: Student’s t-test (N is 
the number of animals per group, Western blotting was done in triplicate). Data are expressed as mean ± SD.
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To understand a possible mechanism behind the memory rescue, the levels of 
pre- and postsynaptic markers in the brain of treated APP/PS1 mice were evalu-
ated by Western blotting. Pre- and postsynaptic markers, such as drebrin and 
synaptophysin, play a crucial role in the synaptic plasticity and are downregulated 
in AD [52, 53]. Loss of synaptophysin correlates with cognitive impairments in AD 
patients and AD transgenic models [53, 54]; Psd95 knockout animals have impaired 
basal synaptic transmission and learning deficit [55]; transgenic animals lacking 
synaptophysin have reduced novel object recognition [56]. Importantly, it has 
been shown that loss of synaptophysin immunoreactivity precedes amyloid plaque 
formation [57, 58]. Preventive treatment of AD transgenic mice with G4 histidine-
maltose PPI dendrimers prevented a decrease in synaptic proteins compared to 
PBS-treated mice [27].
In contrast, G4 histidine-maltose PPI dendrimers did not change the level 
of these synaptic proteins in WT mice, indicating that, most likely, the level of 
their mRNA expression was not affected [27]. Thus it is reasonable to think that 
the increased levels of pre- and postsynaptic proteins are more likely an effect 
of reduced synaptic loss in the treated AD transgenic animals (Figure 8). Thus a 
possible mechanism of memory protection in APP/PS1 could be the synapses were 
shielded by the dendrimers from toxic Aβ oligomers or the toxicity of Aβ oligomers 
were inactivated in the presence of the dendrimers.
4. Conclusions and perspectives
Dendrimers, which represent a type of 3D polymers, have been in the spotlight 
for three decades in biomedical and pharmaceutical research, and their chemistry 
and synthesis are continuously progressing by efforts from many research groups 
and companies. Although there are still many unclear problems in AD, in this chap-
ter, functionalization of dendrimers dedicated to the prevention of memory decline 
in AD pathogenesis has been discussed. Based on the reviewed literature, PPI 
dendrimers have been shown to be useful in the way of the surface functionaliza-
tion, which tuned their biochemical properties. Strikingly, the effect of the surface 
functionalization with histidine and maltose magnified exponentially neuroprotec-
tive properties of PPI dendrimers, resulting in an unprecedented outcome, such as 
memory protection in AD transgenic animals.
In this chapter, I have analyzed the functionalization of PPI dendrimers, 
which tuned the intrinsic properties of PPI dendrimers and converted them into 
a multifunctional drug candidate against Alzheimer’s disease. Modification of the 
dendrimer surface with maltose allowed dendrimers successfully to interfere with 
Aβ(1–42) by forming nontoxic hybrid glycofibrils. Modification of the dendrimer 
surface with histidine improved the ability of the dendrimers to cross the blood–
brain barrier and resulted in synaptic protection. By reducing the level of soluble 
amyloid oligomers, on the one hand, and conferring synapse protection, on the 
other hand, the dendrimers were given multifunctionality against main features 
of AD, synaptic loss, and aggregation of Aβ. These observations, coming out of 
the studies on the interaction of dendrimers with amyloid peptides [18, 26, 27, 31, 
41], carried out in vitro and in vivo, point toward a possible use of dendrimers (in 
particular functionalization of PPI dendrimers with histidine and maltose) as a 
multifunctional drug candidate against Alzheimer’s disease.
However, to find a successful drug against AD, other modifications of histidine-
maltose PPI dendrimers might be required. For example, the ability to cross the 
blood-brain barrier, cell wall penetration, distribution in the specific tissue, and 
biodegradation could be tuned for a particular dendrimer application.
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